Low Prevalence of Antibodies to Glucose-6-Phosphate Isomerase in Patients With Rheumatoid Arthritis and a Spectrum of Other Chronic Autoimmune Disorders

Isao Matsumoto,[1] David M. Lee,[2] Raphaela Goldbach-Mansky,[3] Takayuki Sumida,[4] Carol A. Hitchon,[5] Peter H. Schur,[2] Ronald J. Anderson,[2] Jonathan S. Coblyn,[2] Michael E. Weinblatt,[2] Michael Brenner,[2] Bernard Duclos,[6] Jean-Louis Pasquali,[7] Hani El-Gabalawy,[8] Diane Mathis,[7] and Christophe Benoist[7]

Objective. **Arthritis in the K/BxN mouse model results from pathogenic immunoglobulins that recognize glucose-6-phosphate isomerase (GPI), a glycolytic enzyme residing in the cytoplasm of all cells. Antibodies directed against GPI can, alone, transfer arthritis to healthy recipients. Previous experiments have revealed significant titers of anti-GPI antibodies in the serum of many patients with rheumatoid arthritis (RA). We evaluated the generality of these observations in cohorts of patients with 12 different arthritic and chronic autoimmune diseases and in population-matched healthy control subjects.**

Methods. **Anti-GPI antibodies were assayed in 811 individual serum samples by enzyme-linked immunosorbent assay with 2 forms of GPI, recombinant and native. Results were confirmed by immunoblotting.**

Results. **Several patients had significantly elevated anti-GPI antibody titers, but without the prevalence or the specificity reported previously. Only 15% of RA patients had anti-GPI antibodies (range 12–29% in different cohorts), with a higher prevalence in patients with active disease. Psoriatic arthritis, undifferentiated arthritis, and spondylarthropathy patients also displayed anti-GPI antibodies at similar frequencies (12–25%). Similar titers were detected in a proportion (5–10%) of control subjects or patients with Crohn's disease or sarcoidosis. Very high titers were found in rare cases of RA and systemic lupus erythematosus.**

Conclusion. **No disease-specific pattern of antibody positivity to GPI was apparent. While the antibody-mediated mechanism at play in the mouse model may exemplify a generic mechanism for some forms of arthritis in humans, GPI itself does not appear to be a target common to the majority of RA patients.**

The pathogenesis of arthritis, in particular rheumatoid arthritis (RA), is, for the most part, poorly understood. In particular, the role of joint-specific autoimmunity remains a subject of controversy. It is not known, for example, whether T cells are dominant players in the local inflammation or whether they act

upstream in the process by helping B cells produce pathogenic antibodies (1–3). Studies of the K/BxN mouse, a recently described model of arthritis, have shown that the full scope of arthritic manifestations can be elicited by antibodies.

Similar to RA in humans, the spontaneous disease in this model requires a particular class II allele of the major histocompatibility complex, is chronic, progressive, and symmetric, and results in severe destruction of cartilage and bone. A classic histologic complex of synovitis, leukocyte invasion of the articular cavity, and pannus formation leads to cartilage and bone destruction and is dependent on inflammatory cytokines such as interleukin-1 and tumor necrosis factor α (4).

The immunologic phase of the disease is characterized by the generation of arthritogenic autoantibodies, which is provoked by the autoreactivity—and only partial tolerization—of T lymphocytes expressing the transgenic T cell receptor (5). However, once the pathogenic antibodies have been elicited by the autoimmune reaction, there is no further requirement for lymphoid cells, and the antibodies alone can transfer full-blown arthritis to naive lymphocyte-deficient hosts (5,6). Studies of the K/BxN model also indicated that ubiquitous antigens can be the target of arthritogenic antibodies: those in K/BxN mice recognize the widespread glycolytic enzyme glucose-6-phosphate isomerase (GPI) (7–9).

Does GPI also serve as a target in human diseases? Our initial analyses did not show a high level of anti-GPI antibodies in the sera of RA patients (Korganow AS, Benoist C, Mathis D: unpublished observations). Yet, very strikingly, Schaller et al (10) reported a high frequency of such antibodies in RA patient sera, but not in sera from patients with Sjögren's syndrome (10), although those results have been the subject of debate (11–13). In addition, GPI deposits can be detected on sections of inflamed synovium from RA patients, much as they can in tissues from the joints of K/BxN mice (9,10). Thus, it seemed important to further evaluate the prevalence of antibodies to GPI in a broad range of arthritic conditions compared with other chronic autoimmune/inflammatory diseases.

PATIENTS AND METHODS

Patient cohorts. Patients of the Boston cohort (n = 82) were outpatients under the care of a qualified rheumatologist at the Robert B. Brigham Arthritis Center, Brigham and Women's Hospital (Institutional Review Board protocol no. 2001-P-001620). Medical records were reviewed for signs and symptoms that met the American College of Rheumatology (ACR; formerly, the American Rheumatism Association) criteria for the classification of rheumatic diseases, including RA (14), psoriatic arthritis (PsA) (15), and juvenile rheumatoid arthritis (JRA) (16), and the European Spondylarthropathy Study Group (ESSG) criteria for spondylarthropathy (SpA) (17). The date of disease onset and other laboratory, radiographic, therapeutic, and demographic data were also identified. Laboratory values included the erythrocyte sedimentation rate (ESR; highest value) and rheumatoid factor (RF; titer or unit value). Available radiographs were predominantly of the hands and feet, and had been interpreted by a certified radiologist. All control subjects were free of rheumatic diseases.

The Winnipeg cohort (n = 105) was recruited from patients of community physicians in the Winnipeg area. All were evaluated clinically and followed up at the University of Manitoba Arthritis Center (University of Manitoba Institutional Review Board protocol no. B2001-070). Patients met the ACR criteria for RA (14) or the ESSG criteria for SpA (17); patients with viral arthritis had clinical syndromes typical of these diagnoses. The duration of symptoms in all but 4 patients was between 3 and 12 months. Except for the 4 patients with established RA, none of the patients had taken any disease-modifying antirheumatic drugs (DMARDs). All control subjects were free of rheumatic disease symptoms, and were derived from the same geographic area as the patients.

For the Tsukuba cohort (n = 156), patients with autoimmune disease were randomly recruited from patients attending the autoimmune disease clinic at Tsukuba University Hospital (approved protocol entitled "Research for Detecting Susceptible Genes for Autoimmune Diseases"). The number of tender joints was determined in 49 peripheral joints, and the number of swollen joints was determined according to the presence of effusion and/or synovial thickening in 46 joints (excluding the neck and hips). Erosions identified on radiographs of affected joints at the time of sampling were recorded. The ACR criteria for RA (14) and systemic lupus erythematosus (SLE) (18), and the criteria of the Sjögren's Disease Research Committee of the Ministry of Health and Welfare in Japan (19) were applied. All control subjects were free of rheumatic diseases.

For the National Institutes of Health (NIH) cohort (n = 225), patients with inflammatory arthritis of <1 year's duration and involving ≥1 swollen joint were enrolled into a study of early synovitis at the National Institute of Arthritis and Musculoskeletal and Skin Diseases/NIH (protocol no. 94-AR-194). The number of swollen joints was determined by evaluating patients for the presence of effusion and/or synovial thickening in 66 peripheral joints (hips were excluded). Anteroposterior and lateral radiographs of the hands and feet were obtained at the initial visit and at the 1-year followup visit and were evaluated for the presence of erosions. The ACR criteria for RA (14) and the ESSG criteria for SpA (17) were applied. Patients who did not fulfill either set of criteria were classified as having undifferentiated arthritis. Sera obtained from the initial visit were assessed for a panel of arthritis-associated autoantibodies including anti-Sa, antifilaggrin, anticitrulline, and antikeratin as described (20).

Sera from a cohort of patients with nonarticular chronic autoimmune/inflammatory diseases who were receiving care at the Hôpitaux Universitaires de Strasbourg in Strasbourg, France (n = 60), were also studied. These patients

had a histologically confirmed diagnosis of either sarcoidosis (some with systemic extrapulmonary manifestations) or Crohn's disease.

Enzyme-linked immunosorbent assay (ELISA). All assays were performed in Boston on samples shipped frozen from the participating centers. Recombinant human GPI (rHuGPI) was prepared using the plasmid pGEX-4T3 (Pharmacia, Piscataway, NJ) in which the 16–1692 fragment of human GPI complementary DNA had been inserted (positions from the K03515 sequence). The resulting clone encodes amino acids 1–559 of GPI (the complete coding sequence) linked to glutathione S-transferase (GST) via a thrombin-cleavable linker. Recombinant protein was prepared by growing *Escherichia coli* harboring the pGEX-hGPI plasmid in L-broth (containing 100 μg/ml of ampicillin) at 37°C to an optical density (OD) at 550 nm of 0.6. After growth, 0.1 mM IPTG was added to the medium, and bacterial culture was continued overnight at 20°C.

Cells were centrifuged, the cell pellet was suspended in Buffer A (50 mM Tris HCl, pH 8.0, 0.5 mM EDTA, 0.4M NaCl, 5 mM MgCl$_2$, 5% glycerol, 10 μg/ml of aprotinin, and 0.1 mM dithiothreitol) containing 1 mg/ml of lysozyme. Samples were kept on ice for 1 hour, then frozen and thawed twice. After the addition of EDTA (1 mM final concentration) and Nonidet P40 (0.5% volume/volume), the cell suspension was sonicated 5 times for 1 minute on ice, and cleared by centrifugation. The resulting solution was loaded onto a glutathione–Sepharose column (Pharmacia) equilibrated in phosphate buffered saline (PBS). The column was washed with 10 bed volumes of PBS. The GST-hGPI fusion protein was then eluted with 10 bed volumes of elution buffer (5 mM glutathione, 50 mM Tris HCl, pH 8.0). The amounts and purity of the protein were estimated by sodium dodecyl sulfate–polyacrylamide gel electrophoresis (SDS-PAGE).

This preparation or rabbit muscle GPI (rabGPI; ~50% full-length as estimated by SDS-PAGE) (Sigma, St. Louis, MO) was used at 5 μg/ml (diluted in PBS) to coat microtiter plates (Costar 9017) for 12 hours at 4°C. After washing twice with washing buffer (0.05% Tween 20 in PBS), 2% skim milk (Stop & Shop, Brookline, MA) in PBS was used for blocking of nonspecific binding (30 minutes at 37°C). After 2 washes, sera (diluted 1:100 in essentially all experiments) were added, and the plates were incubated for 12 hours at 4°C or for 2 hours at 37°C. After washing, alkaline phosphatase (AP)–conjugated anti-human IgG (Fc fragment specific; Jackson Immuno-Research, West Grove, PA) was added to the plates (1:1,000 dilution) for 1 hour at room temperature. After 3 washes, color was developed with AP reaction solution (containing 9.6% diethanolamine, 0.25 mM MgCl$_2$, pH 9.8, with AP substrate tablets [1 AP tablet per 5 ml of AP reaction solution]; Sigma). Plates were incubated for 1 hour at room temperature, and the OD$_{405 \text{ nm}}$ was measured by plate spectrophotometry. Determinations were performed in triplicate and standardized between experiments by reference to a highly positive human anti-GPI serum.

Anti-GPI reactivity to each antigen was corrected by subtracting the OD readings for anti-GPI reactivity in parallel wells coated with matched molar amounts of GST (for rHuGPI) or bovine serum albumin (BSA; for rabGPI). OD values for the controls were usually in the range of 0.26–0.62 and 0.13–0.21, respectively. Approximately 5% of sera exhib-

ited high reactivity (>1.0) to GST alone. These OD values were tabulated and then converted to 2 anti-GPI indices. Index 1 combined the reactivity against either antigen, and was calculated as follows:

$$\text{Index } 1(i) = \sqrt{(x_i^2 + y_i^2)}$$

where x_i and y_i are the OD readings for rabGPI and rHuGPI of serum i, respectively. Index 2 considered only the shared reactivity against both antigens and was calculated as follows:

$$\text{Index } 2(i) = \min(x_i, y_i)$$

where min represents minimum.

For the competitive ELISA, patient sera were diluted to yield similar anti-GPI OD readings on rHuGPI-coated plates. Several wells were set up in parallel, with no or with graded amounts of soluble rHuGPI (5–100 μg/ml) added to rHuGPI-coated plates, followed immediately by the addition of patient sera. Plates were then incubated for 2 hours at 20°C. The next steps of the ELISA were performed as described above.

Immunoblot analysis. To prepare human GPI that was free of the GST moiety, rHuGPI-GST was digested by thrombin according to the manufacturer's protocol (Pharmacia). Preliminary gel electrophoresis showed these preparations to be $>90\%$ digested. The digestion mixture (still including the 26-kd GST fragment) was separated by SDS-PAGE and electroblotted onto polyvinylidene difluoride membranes (Bio-Rad, Jupiter, CA). After blocking with 5% weight/volume skim milk in PBS (12 hours at 4°C), the membrane was cut into thin strips. Each strip was incubated with 1 ml of patient serum diluted 1:100 in PBS supplemented with 5% w/v skim milk powder (2 hours at 20°C). Bound antibody was visualized with AP-conjugated anti-human IgG (Jackson ImmunoResearch), and visualized with AP reaction solution containing 0.4 mM nitroblue tetrazolium (Bio-Rad) and 0.4 mM 5-bromo-4-chloro-3-indolylphosphate-*p*-toluidine salt (Bio-Rad) for 3 minutes at room temperature.

RESULTS

Findings in the patient cohorts. In order to investigate the broadest possible group of patients, we analyzed several independent cohorts. The characteristics of each of the cohorts are as follows.

The Boston cohort (n = 119) provides a cross-disease representation of patients receiving followup care at the Brigham and Women's Hospital Arthritis Center (Table 1). Disease duration at the time of serum collection varied, ranging from 0.2 years to 32 years. These patients were categorized by clinician's assessment as having "inflammatory" (presenting with acute or ongoing inflammatory manifestations at the time of serum collection) or "stable" (controlled disease; not very active at the time of sampling) disease. A variety of treatments were being given at the time of sampling; 79% were being treated with at least 1 DMARD. The

Table 1. Demographics of the Boston cohort*

	Healthy controls (n = 37)	RA		PsA (n = 17)	JRA (n = 4)	SpA (n = 6)
		RF+ (n = 41)	RF− (n = 14)			
Age, mean ± SD (range) years	44 ± 15 (23–84)	55 ± 17 (17–81)	57 ± 17 (28–73)	43 ± 12 (24–50)	29 ± 6.5 (23–38)	35 ± 10 (24–50)
% female	63	84	93	59	50	0
Symptom duration, mean years	–	9.0	7.0	6.8	17.1	8.23
ESR, mean ± SD mm/hour	–	60 ± 25	57 ± 37	46 ± 31	76 ± 42	48 ± 27
% with RF >15 units	–	100	0	0	100	0
% with erosions	–	74	50	25	67	40
% taking steroids	–	45	57	21	75	17
% taking DMARDs	–	88	79	86	75	67

* Radiographs were available for determination of erosions in only 61 of the 82 patients. RA = rheumatoid arthritis; RF = rheumatoid factor; PsA = psoriatic arthritis; JRA = juvenile rheumatoid arthritis; SpA = spondylarthropathy; ESR = erythrocyte sedimentation rate; DMARDs = disease-modifying antirheumatic drugs.

control group (n = 37) was collected at the Joslin Diabetes Center, largely from the same New England population, and consisted primarily of healthy partners of diabetic patients as well as a subset of laboratory workers. These subjects were free of autoimmune disease.

The Winnipeg cohort (55 affected and 50 controls) was derived primarily from an early synovitis clinic at the University of Manitoba Arthritis Centre in Winnipeg (Table 2). Patients varied with regard to disease duration at the time of serum collection.

The Tsukuba cohort (n = 205) provides a cross-disease presentation of Japanese patients randomly chosen from patients receiving followup care at the Autoimmune Disease Clinic of Tsukuba University Hospital (Table 3). The diagnoses included RF-positive RA (n = 70), seronegative RA (n = 28), SLE (n = 38), and Sjögren's syndrome (n = 20). Patients varied with regard to disease duration at the time of serum collection, and

they were receiving a diverse range of treatments. This cohort also included both active and stable forms of disease at the time of sampling. The healthy donor samples (n = 49) were collected from hospital and laboratory volunteers at Tsukuba University.

The NIH cohort (n = 225) represents a set of patients whose serum was sampled close to the onset of their arthritis, with synovitis of <1 year's duration (Table 4). The diagnoses included seropositive RA (n = 71), seronegative RA (n = 34), SpA (n = 40), and undifferentiated arthritis (n = 80). While a healthy control group was not included, this cohort is interesting because it has already been thoroughly characterized for the association of synovitis with a panel of autoantibodies (20), permitting a test of the correlation of anti-GPI antibodies with other RA-related antibody specificities.

Nonarticular chronic autoimmune/inflammatory diseases were represented by a set of sera, all sampled at the time of initial presentation, from the Hôpitaux

Table 2. Demographics of the Winnipeg cohort, all of whom had disease of recent onset*

	RA		PsA (n = 3)	Arthralgias (n = 16)	Viral (n = 3)
	RF+ (n = 31)	RF− (n = 2)			
Age, mean (range) years	45 (16–76)	59 (46–73)	28 (20–37)	42 (20–63)	30 (17–39)
% female	60.7	100	66.7	73.3	66.7
% Caucasian	66.7	100	66.7	81.3	100
Tender joint count, mean ± SD	12.6 ± 10	23	10 ± 4.4	9.8 ± 14.2	0
Swollen joint count, mean ± SD	10 ± 7.5	24	3.3 ± 2.1	3 ± 4	8
ESR, mean ± SD mm/hour	24.4 ± 26	26.5 ± 20	38.3 ± 47	7.5 ± 6	11 ± 9
CRP, mean ± SD mg/dl	17.7 ± 25	8 ± 5.7	39.6 ± 61	4.3 ± 0.9	4
% taking prednisone	6	50	0	0	0
% taking DMARDs	9.6	50	0	6.3	0

* This cohort includes 50 population-matched controls. RA = rheumatoid arthritis; RF = rheumatoid factor; PsA = psoriatic arthritis; ESR = erythrocyte sedimentation rate; CRP = C-reactive protein; DMARDs = disease-modifying antirheumatic drugs.

Table 3. Demographics of the Tsukuba cohort*

| | Healthy controls (n = 49) | RA | | SLE (n = 38) | SS (n = 20) |
		RF+ (n = 70)	RF− (n = 28)		
Age, mean ± SD years	29 ± 8	58 ± 13	43 ± 17	50 ± 13	54 ± 11
% female	66	89	65	90	90
Symptom duration, mean ± SD months	–	129 ± 144	128 ± 119	171 ± 105	84 ± 102
Tender joint count, mean ± SD	–	5 ± 3	4 ± 3	0.1 ± 0.3	0
Swollen joint count, mean ± SD	–	4 ± 3	3 ± 3	0.1 ± 0.3	0
ESR, mean ± SD mm/hour	–	53 ± 32	30 ± 17	14 ± 4	47 ± 18
CRP, mean ± SD mg/dl	–	1.8 ± 2.2	1 ± 1.2	0.3 ± 0.5	0.4 ± 0.9
% with RF >20 units	–	100	0	20	90
% with erosions	–	64	62	0	0
% taking prednisone	–	54	62	90	0
% taking DMARDs	–	82	75	0	0

* The number of tender joints was determined in 49 peripheral joints; the number of swollen joints was determined according to the presence of effusion and/or synovial thickening in 46 joints (excluding the neck and hips). Erosions were identified on radiographs of affected joints taken at the time of sampling. RA = rheumatoid arthritis; RF = rheumatoid factor; SLE = systemic lupus erythematosus; SS = Sjögren's syndrome; ESR = erythrocyte sedimentation rate; CRP = C-reactive protein; DMARDs = disease-modifying antirheumatic drugs.

Universitaires de Strasbourg (Strasbourg, France). Twenty patients presented with a histologically confirmed diagnosis of sarcoidosis (mean age 40 years, range 27–59 years), of which 11 had systemic extrapulmonary manifestations. Forty patients had a diagnosis of Crohn's disease that had been confirmed histologically (mean age 33, range 19–44 years). Sera from these patients were also sampled at the time of diagnosis (32 patients) or at the time of an acute disease flare (8 patients).

For all cohorts, the sera were aliquoted shortly after collection (within 8 hours in almost all instances), and were frozen at −80°C; aliquots were thawed and refrozen, at most, only once after this. Significant problems with the reproducibility of the anti-GPI assay results occurred with sera that had been frozen and thawed multiple times or sera that had been kept for long periods of time at 4°C (data not shown). It is possible that the GPI present in the serum samples, albeit at a low level, may influence the stability of the anti-GPI reactivity under such conditions.

Validation of technical choices for the ELISA. The initial report of anti-GPI reactivity in RA sera elicited objections to the validity of the antigen used in the ELISA or the specificity of the assay conditions (11–13). We tested a number of experimental variables,

Table 4. Demographics of the National Institutes of Health cohort*

| | RA | | SpA (n = 40) | UA (n = 80) |
	RF+ (n = 71)	RF− (n = 34)		
Age, mean ± SD years	47 ± 12	44 ± 14	37 ± 11	41 ± 14
% female	60	74	63	7
% Caucasian	77	92	100	80
Symptom duration, mean ± SD weeks	33 ± 17	30 ± 24	31 ± 36	35 ± 37
Tender joint count, mean ± SD	19 ± 12	22 ± 12	5 ± 10	5 ± 5
Swollen joint count, mean ± SD	13 ± 9	16 ± 11	2 ± 2	3 ± 3
ESR, mean ± SD mm/hour	45 ± 28	41 ± 31	40 ± 30	33 ± 30
CRP, mean ± SD mg/dl	1.8 ± 1.8	1.8 ± 2.0	1.9 ± 3.2	1.5 ± 1.9
% with RF >20 units	100	0	5	12 (15)
% with erosions	45	36	12	16
% taking prednisone	34	44	25	12
% taking DMARDs	38	35	18	13

* The number of swollen joints was determined by evaluating patients for the presence of effusion and/or synovial thickening in 66 peripheral joints (hips were excluded). Radiographs were available for determination of erosions in only 183 of the 225 patients. RA = rheumatoid arthritis; RF = rheumatoid factor; SpA = spondylarthropathy; UA = undifferentiated arthritis; ESR = erythrocyte sedimentation rate; CRP = C-reactive protein; DMARDs = disease-modifying antirheumatic drugs.

Figure 1. Enzyme-linked immunosorbent assay (ELISA) conditions for anti–glucose-6-phosphate isomerase (anti-GPI) determination. **A,** Reactivity of human sera (Boston cohort; different diagnoses pooled) against both recombinant (rec.) human GPI (anti-huGPI; y-axis) and purified rabbit muscle GPI (anti-rabGPI; x-axis). ELISAs were performed against each antigen as described in Patients and Methods, with sera diluted 1:100. Each data point represents the optical density (OD) value for a single serum sample (corrected by subtracting background reactivity against bovine serum albumin or glutathione S-transferase, respectively). **B,** Comparison between reactivities at 4°C (4C) and 37°C (37C). ELISAs were performed with either rabbit GPI (left) or recombinant human GPI (right), and the data were processed as for **A**. Each data point represents a single serum sample.

which, given the divergent views, are worth detailing here. We utilized 2 forms of antigen, thus guarding against problems with spurious cross-reactivity or contaminants in one or another preparation.

First, we adapted our previous ELISA (7) with full-length rHuGPI, expressed in *E coli* as a GST fusion protein, and purified to homogeneity by affinity chromatography on glutathione–Sepharose (>90% purity on SDS-PAGE, devoid of any major contaminant). Free GST purified in parallel was used as a control. Second, because this recombinant form of GPI may not have the same conformation or posttranslational modifications as the natural enzyme, we also utilized native GPI purified from rabbit liver. This is also the antigen used by Schaller et al (10), thus allowing a direct comparison with their results. While not strictly identical in amino acid sequence to the human protein (93% identity), this form of GPI provides a native conformation of the enzyme with normal posttranslational modifications. SDS-PAGE showed this preparation to contain ~50% GPI, as previously reported (12). BSA was used as the negative control in this instance.

As shown in Figure 1A, reactivity to both forms of GPI was not always correlated. Some sera did show reactivity to both, but a significant proportion reacted very preferentially to one or the other of the antigens (in contrast, serum from arthritic K/BxN mice reacted vigorously to both forms, even at high dilutions). Thus, we systematically tested both forms of antigen. On the other

hand, the overall conclusions concerning association with disease proved similar with either antigen source (see below), and for tabulations of reactivity frequencies, we calculated combined indices, integrating reactivity to either or both antigens (see Patients and Methods).

Assay conditions were also tested systematically. The optimal concentration of coating antigen was tested with K/BxN serum as a guide, and a number of blocking agents were tested, lest one lead to a higher background value through adventitious reactivity. In several assays, we found no significant difference in background reactivity levels when using BSA (1–4%), commercial skim milk (2–5%), or horse serum (5%) as blocking agents (data not shown). Because Schaller et al (10) had used incubations with test sera at 37°C, rather than our incubation temperature of 4°C, we also tested the 2 temperatures in parallel. As shown in Figure 1B, there was no significant difference between the 2 conditions, and the results largely correlated (with a higher overall binding at 4°C, as might be expected). In the full analysis, binding was tested at both temperatures for almost all sera, with very similar conclusions (but, for simplicity, only the results obtained at 4°C are shown below).

All sera were tested in parallel at a dilution of 1:100, using for standardization a serum pool from arthritic K/BxN mice, which allowed comparisons between experiments. The primary readings were pro-

Figure 2. Enzyme-linked immunosorbent assays were performed with both rabbit glucose-6-phosphate isomerase (rabGPI) and recombinant human GPI (rHuGPI) as targets, and the data were corrected by subtraction of background values, as described in Figure 1. The assay conditions were maintained constant between experiments, using for a constant reference a pool of K/BxN mouse sera. Each data point represents an individual patient; the diagnoses are color-coded as indicated. RA = rheumatoid arthritis; RF+ = rheumatoid factor positive; seroneg = seronegative; PsA = psoriatic arthritis; SLE = systemic lupus erythematosus; SpA = spondylarthropathy; UA = undifferentiated arthritis.

cessed by subtracting OD readings of control wells (coated with GST and BSA for rHuGPI-GST and rab-GPI, respectively). The values were not processed further, even though linearity did drop off at high OD values, leading to log-like compression of the readings. As will be seen below, further processing would not have substantially altered the basic conclusions on the relative distribution of values in the patient and control groups.

ELISA detection of anti-GPI reactivity. Combined ELISA results for the 811 sera are displayed in Figure 2, where reactivities against rabGPI and rHuGPI are shown separately for each cohort and are color-coded for disease status. In the different cohorts, there was no strikingly different distribution of anti-GPI reactivities in patients with RA, patients with other arthritic diseases, and controls. A continuous spectrum of values was observed, with no obvious cutoff between positive and negative sera; the large majority of samples yielded OD readings of ≤1.0 with either antigen. A few samples showed greater reactivity (>1.0) with either or both antigens. In the Boston cohort, and to some extent in the Tsukuba cohort as well, these included a greater propor-

tion of patients with arthritis, but this was not necessarily RA. This was not confirmed in the Winnipeg cohort, where more than half of the sera with higher anti-GPI titers were from healthy control subjects.

Two "anti-GPI indices" were calculated for the entire data set, based on the reactivity to both rabGPI and rHuGPI antigens. The first index combines the reactivity against both antigens, since it is possible that unique epitopes are present on only one antigen form. On the other hand, since either antigen preparation might contain contaminating proteins that would confound the analysis (trace bacterial contaminants for the recombinant protein or other muscle proteins for the rabbit muscle GPI), the second index scores more favorably the shared reactivity against both antigens. For both of these indices, cutoff points for positivity were calculated as the 95% percentile of the values in control subjects.

The proportion of positive sera was calculated for the various diagnoses across all cohorts (Table 5). While there was a trend toward a higher frequency of reactivity in sera from arthritis patients, no measure clearly distin-

Table 5. Frequency of anti–GPI-positive sera in 811 patients with different pathologic conditions*

Diagnosis	% anti-GPI positive		Anti-GPI index		No. of sera
	Rabbit GPI	rHuGPI	Index 1†	Index 2‡	
Nonarthritic controls	5.3	5.3	7.0	6.1	114
Seropositive rheumatoid arthritis	5.4	13.0	14.6	7.5	239
Seronegative rheumatoid arthritis	9.3	9.3	15.5	11.3	97
Juvenile rheumatoid arthritis	10.5	5.3	21.1	25.0	19
Psoriatic arthritis	5.0	15.0	15.0	5.0	20
Spondylarthropathy	5.7	17.0	24.5	0.0	53
Systemic lupus erythematosus	2.6	7.7	7.7	5.0	39
Sjögren's syndrome	5.0	0.0	5.0	5.0	20
Viral arthritis	33.3	33.3	33.3	10.5	3
Undifferentiated arthritis	2.2	14.4	12.9	10.3	139
Undifferentiated arthritis (RF+)	12.5	0.0	12.5	15.0	8
Crohn's disease	5.0	5.0	7.5	33.3	40
Sarcoidosis	5.0	10.0	10.0	7.6	20

* The proportion of positive sera (those above a cutoff defined as the 95% percentile of control sera) was calculated independently for optical density readings corrected against rabbit glucose-6-phosphate isomerase (GPI) and recombinant human GPI (rHuGPI) antigens. RF = rheumatoid factor.
† Anti-GPI index 1 combines the reactivity against both the rabbit and the recombinant human GPI antigens (as the square root of $[(rabbit\ GPI)^2 + (rHuGPI)^2]$), and positivity was determined with the same cutoff.
‡ Anti-GPI index 2 tracks the shared reactivity against both antigens (the minimum reading).

guished reactivities in RA patients. Neither the combined anti-rabGPI and anti-rHuGPI reactivities of index 1 nor the dual reactivities of index 2 highlighted any disease group. The slightly increased frequencies in RA patients were not specific to the disease, since sera from patients with PsA and with SpA exhibited similar frequencies. Patients with Crohn's disease showed the highest frequency of dual reactivity.

A very small subset of patients had considerably higher titers against both forms of GPI (detectable at dilutions of ≥1:5,000). Again, there was no disease specificity in this group, since these very high titers were found in 1 SLE patient, 1 seronegative RA patient, and 1 RA patient with severe extraarticular manifestations.

We attempted to correlate anti-GPI titers with disease parameters within the RA group. No association was found between anti-GPI reactivities and either the patient's sex, age at disease onset, or disease duration, the presence of RF (seronegative RA patients had a slightly higher prevalence of reactivity, particularly those

in the Boston cohort) or radiographic erosions (the 3 RA sera with the highest anti-GPI titers were from patients with limited radiographic erosions), or the type of treatment. On the other hand, active disease correlated with somewhat higher anti-GPI antibody levels. As shown in Figure 3, patients with the more active forms of RA showed a higher prevalence of serum anti-GPI positivity (27.3% positive for anti-rabGPI, 18.2% positive for anti-rHuGPI, 36.4% for index 1, and 22.7% for index 2 in the "inflammatory" RA subgroup versus 6.1%, 15.2%, 24.2%, and 9.1%, respectively, in the "stable" RA subgroup; $P = 0.008$, $P = 0.19$, $P = 0.04$, and $P = 0.03$, respectively, by t-test).

Arthritogenic antibodies in K/BxN mice have a very high affinity for GPI, and it was conceivable that sera from patients with arthritis had anti-GPI antibodies of higher affinity than those from controls (21). In an attempt to address this question, we performed competitive ELISA experiments (higher affinity antibodies being more easily displaced from the target by low concentrations of soluble competitor). No significant

Anti-GPI vs inflammatory status

Figure 3. Correlation of higher anti–glucose-6-phosphate isomerase (anti-GPI) reactivities with inflammatory status. Rheumatoid arthritis (RA) patients (Boston cohort only; both seropositive and seronegative patients) were categorized by their disease status (determined by a rheumatologist prior to determining anti-GPI antibody values) at the time the serum sample was collected. Those with stable RA had long-term disease that was relatively controlled, with mainly dormant sequellar lesions; those with inflammatory RA had active inflammatory lesions at the time of sampling. Values are the anti-GPI index 1 data (see Table 5); each data point represents an individual patient.

rHuGPI O.D.	3.5	2.044	1.646	1.973	2.347	2.481	2.717	2.863	3		0.294	0.472	0.51	1.49
rabGPI O.D.	3.5	0.825	1.326	0.4	1.188	0.53	1.552	0.825	3		0.046	0.023	0.04	0.33
Diagnosis	SnRA	PSA	SnRA	RA	RA	RA	PSA	SnRA	RA	K/BxN	C	C	C	C

Figure 4. Correlation of anti–glucose-6-phosphate isomerase (anti-GPI) reactivities on enzyme-linked immunosorbent assay with reactivities on Western blots. Individual sera from patients with arthritis (lanes 1–9) were used to probe electroblot strips on which recombinant human GPI (rHuGPI; a whole gel was blotted, and strips were cut longitudinally) had been blotted. Lane 10 was probed with control serum from an arthritic K/BxN mouse; lanes 11–14 were probed with sera from healthy subjects. The position of GPI (60 kd) is indicated at the left. O.D. = optical density; rabGPI = rabbit GPI; SnRA = seronegative rheumatoid arthritis; PSA = psoriatic arthritis; RA = rheumatoid arthritis; C = control.

differences were observed between RA and control sera in these assays, but the results indicated that the anti-GPI antibodies present in human sera were of lower affinity than those present in sera from the K/BxN mouse model (data not shown).

The NIH cohort (Table 4) (20) is composed of sera from a clinical spectrum of patients with arthritis of recent onset. Sera from this cohort have been well characterized for antibodies that have previously been associated with RA: anticitrulline, antikeratin, antifilaggrin, and anti-Sa (22–25). As previously described, these antibodies were significantly associated with the diagnosis of RF-positive RA in this patient cohort ($0.00001 < P < 0.0005$) (20). However, antibodies to GPI showed no correlation with these RA-associated antibodies ($0.10 < P < 0.90$, by 2-tailed t-test) (data not shown). There was only a slight correlation between anti-rabGPI titers (but not anti-rHuGPI) and positivity for antinuclear antibodies ($P < 0.02$, corrected for multiple sampling).

Confirmation of anti-GPI reactivity by Western blotting. Questions have been raised about the purity of the commercial rabGPI preparation, with the suggestion by Schubert et al (12) that a proportion of the serum antibodies from their RA patients were reactive against contaminating creatine kinase. Although our study attempted to avoid such problems by combining measurements with 2 different antigens, it was nevertheless important to verify that the anti-GPI antibodies we detected were indeed reactive to GPI. This was verified by Western blotting, with strips of electroblot membrane onto which purified rHuGPI and rabGPI had been transferred after SDS-PAGE separation. Electroblotting affords the spatial resolution to distinguish true anti-GPI signals from reaction against contaminants, but would have been impractical to apply to the whole set of 811 samples. Analyses were therefore performed on subsets of patient and control sera that yielded OD readings >1.0 in the ELISA assays.

The example shown in Figure 4 confirms that the strong positive ELISA readings indeed corresponded to anti-GPI antibodies in the majority of cases (lanes 1, 2, 3, 6, 7, 8, 9, and 14). Some sera detected other bands (lanes 4 and 5). However, electroblot analysis confirmed the absence of disease specificity of anti-GPI antibodies for RA. Among the sera shown in Figure 4, clear anti-GPI reactivities were seen with seronegative RA (lane 1), PsA (lanes 2 and 7), and seropositive RA (lane 9).

DISCUSSION

As previously reported by other investigators (10), we detected reactivity to GPI in the serum of a number of individuals. We confirmed this reactivity to be focused on GPI itself. Yet, there were several key differences in the results from the two studies:

The strong specificity for RA patients found by Schaller et al (10) was not reproduced in our studies. We found far less difference between RA patients and nonarthritic control subjects. We found the overall frequency in RA patients to be slightly higher than that in controls, but it was by no means predominant (50 of 336 RA patients [14.8%] versus 8 of 114 controls [7.0%]; $P = 0.045$). There was some degree of variation between cohorts. The Boston cohort (16 of 55 RA patients [29.0%] versus 2 of 37 controls [5.4%]; $P = 0.01$) showed a stronger distinction between RA patients and controls than did the Winnipeg cohort (4 of 33 RA patients [12.1%] versus 7 of 31 controls [22.6%]; P not significant). Yet, in no instance did the frequency in RA patients reach the 60% value previously reported (10). Lowering the cutoff point used for positivity did not improve the discrimination between RA patients and controls (data not shown), nor did various calculated indices encompassing the reactivity to either or both forms of GPI (Table 5).

No specificity for RA compared with other arthritic diseases was observed in our study. Positive anti-GPI titers were found in other groups of patients, such as those with PsA and SpA, but, again, in only subsets of these patients. Positive titers were also found in sera from patients with Crohn's disease and patients with sarcoidosis.

Why do our results differ? Aside from the variability between cohorts discussed above, an explanation may lie in the very aggressive forms of RA sampled in the study by Schaller et al (10); a large number of those patients had Felty's syndrome. The very high prevalence of anti-GPI in the Schaller study may thus have reflected a preponderance of the Felty's syndrome form of RA. Our cohorts did not have this particular condition, but we did find a slight relationship between the aggressiveness of the arthritis and the indices of anti-GPI (Figure 3). The peculiarity of Felty's syndrome patients may be worth reexamining in future studies. Anti-GPI titers, which were highest at peaks of disease activity, may thus subside in more latent phases. However, all samples from the NIH cohort were obtained at disease onset, likely in an inflammatory setting, and the values were not significantly higher overall than those in the other groups of arthritis patients.

The pathogenic potential of the anti-GPI antibodies present in these patients is a key question. It may well be that GPI is only one of several autoantigens able to serve as a target for pathogenic antibodies. In very preliminary analyses, anti-GPI antibodies from patients with the highest titers were affinity-purified and injected into naive BALB/c mice, the strain most susceptible to arthritis transfer by K/BxN serum. In these early tests, no lasting disease was observed (Matsumoto I: unpublished observations). Yet, the interpretation of these findings is complicated by possible incompatibility between human and mouse complement and Fc receptor signaling pathways, both of which are essential to arthritogenesis (26). These results will need to be reexamined in "humanized" test systems.

In conclusion, GPI itself may prove to be the target of autoimmune attack in some patients, as it is in K/BxN mice. It is now clear that it does not provide, with the ELISA and electroblot assays now available, a useful general assay for the discrimination of RA.

REFERENCES

1. Feldmann M, Brennan FM, Maini RN. Rheumatoid arthritis. Cell 1996;85:307–10.
2. Benoist C, Mathis D. A revival of the B cell paradigm for rheumatoid arthritis pathogenesis? Arthritis Res 2000;2:90–4.
3. Firestein GS, Zvaifler NJ. How important are T cells in chronic rheumatoid synovitis? II. T cell–independent mechanisms from beginning to end. Arthritis Rheum 2002;46:298–308.
4. Ji H, Pettit A, Ohmura K, Ortiz-Lopez A, Duchatelle V, Degott C, et al. Critical roles for interleukin-1 and tumor necrosis factor-α in antibody-induced arthritis. J Exp Med 2002;196:77–85.
5. Korganow A-S, Ji H, Mangialaio S, Duchatelle V, Pelanda R, Martin T, et al. From systemic T cell self-reactivity to organ-specific autoimmune disease via immunoglobulins. Immunity 1999;10:451–61.
6. Kouskoff V, Korganow A-S, Duchatelle V, Degott C, Benoist C, Mathis D. Organ-specific disease provoked by systemic autoreactivity. Cell 1996;87:811–22.
7. Matsumoto I, Staub A, Benoist C, Mathis D. Arthritis provoked by linked T and B cell recognition of a glycolytic enzyme. Science 1999;286:1732–5.
8. Basu D, Horvath S, Matsumoto I, Fremont DH, Allen PM. Molecular basis for recognition of an arthritic peptide and a foreign epitope on distinct MHC molecules by a single TCR. J Immunol 2000;164:5788–96.
9. Matsumoto I, Maccioni M, Lee DM, Maurice M, Simmons B, Brenner M, et al. How antibodies to a ubiquitous cytoplasmic enzyme may provoke joint-specific autoimmune disease. Nat Immunol 2002; 3:360–5.

10. Schaller M, Burton DR, Ditzel H. Autoantibodies to GPI in rheumatoid arthritis: linkage between an animal model and human disease. Nat Immunol 2001;2:746–53.
11. Kassahn D, Kolb C, Solomon S, Bochtler P, Illges H. Few human autoimmune sera detect GPI [letter]. Nat Immunol 2002;3:411–2.
12. Schubert D, Schmidt M, Zaiss D, Jungblut PR, Kamradt T. Autoantibodies to GPI and creatine kinase in RA [letter]. Nat Immunol 2002;3:411.
13. Schaller M, Benoit VM, Ditzel HJ. Response [letter]. Nat Immunol 2002;3:412–3.
14. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315–24.
15. Veale D, Rogers S, FitzGerald O. Classification of clinical subsets in psoriatic arthritis. Br J Rheumatol 1994;33:133–8.
16. Cassidy JT, Levinson JE, Bass JC, Baum J, Brewer EJ Jr, Fink CW, et al. A study of classification criteria for a diagnosis of juvenile rheumatoid arthritis. Arthritis Rheum 1986;29:274–81.
17. Dougados M, van der Linden S, Juhlin R, Huitfeldt B, Amor B, Calin A, et al, and the European Spondylarthropathy Study Group. The European Spondylarthropathy Study Group preliminary criteria for the classification of spondylarthropathy. Arthritis Rheum 1991;34:1218–27.
18. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982;25:1271–7.
19. Homma M, Tojo T, Akizuki M, Yamagata H. Criteria for Sjögren's syndrome in Japan. Scand J Rheumatol Suppl 1986;61:26–7.
20. Goldbach-Mansky R, Lee J, McCoy A, Hoxworth J, Yarboro C, Smolen JS, et al. Rheumatoid arthritis associated autoantibodies in patients with synovitis of recent onset. Arthritis Res 2000;2:236–43.
21. Maccioni M, Zeder-Lutz G, Huang H, Ebel C, Gerber P, Hergueux J, et al. Arthritogenic monoclonal antibodies from K/BxN mice. J Exp Med 2002;195:1071–7.
22. Despres N, Boire G, Lopez-Longo FJ, Menard HA. The Sa system: a novel antigen-antibody system specific for rheumatoid arthritis. J Rheumatol 1994;21:1027–33.
23. Palosuo T, Lukka M, Alenius H, Kalkkinen N, Aho K, Kurki P, et al. Purification of filaggrin from human epidermis and measurement of antifilaggrin autoantibodies in sera from patients with rheumatoid arthritis by an enzyme-linked immunosorbent assay. Int Arch Allergy Immunol 1998;115:294–302.
24. Sebbag M, Simon M, Vincent C, Masson-Bessiere C, Girbal E, Jean-Jacques D, et al. The anti-perinuclear factor and the so-called anti-keratin antibodies are the same rheumatoid arthritis-specific autoantibodies. J Clin Invest 1995;95:2672–9.
25. Schellekens GA, de Jong B, van den Hoogen F, van de Putte L, van Venrooij WJ. Citrulline is an essential constituent of antigenic determinants recognized by rheumatoid arthritis-specific autoantibodies. J Clin Invest 1998;101:273–281.
26. Ji H, Ohmura K, Mahmood U, Lee DM, Hofhuis FMA, Boackle SA, et al. Arthritis critically dependent on innate immune system players. Immunity 2002;16:157–68.